Evidence mapPaperPMID 41463285Full record

ReviewCancers2025

HCC in the Era of Emerging MASH: The Role of Ultrasound in Surveillance and New Sonographic Features in Diagnosis.

Antonio Giorgio, Massimo De Luca, Anna Lombardi, Emanuela Ciracì, Valeria Cosima Rollo, Antonella Di Sarno, Luca Montesarchio, Giuseppe Stella, Valentina Giorgio

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Antonio GiorgioLiver Unit, Athena Clinical Center, Piedimonte, 81016 Caserta, Italy.ORCID 0000-0003-4606-7780
Massimo De LucaLiver Unit, Cardarelli Hospital, 80131 Naples, Italy.ORCID 0000-0003-1675-1696
Anna LombardiDepartment of Translational Medical Sciences, Federico II University Hospital, 80131 Naples, Italy.ORCID 0000-0001-6968-4947
Emanuela CiracìOstuni Civic Hospital, Internal Medicine, Ostuni, 72017 Brindisi, Italy.ORCID 0000-0001-9942-0766
Valeria Cosima RolloOstuni Civic Hospital, Internal Medicine, Ostuni, 72017 Brindisi, Italy.ORCID 0009-0008-1129-5111
Antonella Di SarnoDepartment of Endocrinology, Diabetology, Andrology and Clinical Nutrition, Federico II University Hospital, 80131 Naples, Italy.ORCID 0000-0003-3620-3275
Luca MontesarchioGeneral Surgery with Minimally Invasive Oncology and High Specialization in Esophageal-Gastric Procedures, Cardarelli Hospital, 80131 Naples, Italy.ORCID 0000-0002-6081-9945
Giuseppe StellaUnità Operativa Semplice Dipartimentale Spina Bifida e Uropatie Congenite, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.ORCID 0000-0003-2179-5992
Valentina GiorgioUnità Operativa Semplice Dipartimentale Spina Bifida e Uropatie Congenite, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.ORCID 0000-0002-7448-8710

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional ultrasound (US) has long been central to hepatocellular carcinoma (HCC) surveillance in cirrhotic patients, due to its low cost, wide availability, non-invasiveness, and adequate sensitivity for detecting small nodules. However, its specificity in distinguishing HCC from other lesions is limited. Contrast-enhanced ultrasound (CEUS) has significantly improved the characterization of nodules first identified on conventional US. Yet, when CEUS is performed using sulfur hexafluoride (SonoVue)-the only contrast agent available in Western countries-assessment remains restricted to a single nodule per examination, and enhanced CT or MRI is still required for full characterization and staging. In clinical settings, such as hepatology, internal medicine, infectious diseases, and surgery, CEUS offers the advantage of immediate availability, enabling rapid characterization of suspicious nodules in cirrhotic livers and facilitating timely therapeutic decisions. Although the introduction of direct-acting antivirals (DAAs) has substantially reduced HCV-related HCC, HCC incidence is increasingly driven by metabolic dysfunction-associated steatohepatitis (MASH). Evidence on surveillance strategies for MASH patients remains limited, and current EASL guidelines recommend monitoring only patients with >F2 fibrosis. Additionally, the effectiveness of US in obese or diabetic/obese populations is under ongoing investigation; abbreviated non-contrast MRI has been proposed as an alternative surveillance tool, but its adoption would entail significant economic implications for healthcare systems. HCC arising from MASH-sometimes even without cirrhosis-exhibits different sonographic and pathological features. Instead of small, hypoechoic nodules, typically seen in HCV-related cirrhosis, clinicians increasingly encounter larger or multiple lesions, often accompanied by macrovascular invasion, limiting access to curative treatments. Furthermore, typical CEUS LI-RADS patterns are less frequently observed. This review summarizes the evolving US findings in the era of MASH-related HCC and underscores the continued importance of US as the primary imaging tool in routine clinical practice.

Indexed as

artificial intelligence (AI)contrast-enhanced ultrasound (CEUS)HCC surveillancehepatocellular carcinoma (HCC)metabolic dysfunction-associated steatohepatitis (MASH)ultrasound (US)

Identifiers

PMID41463285
PMCPMC12730772

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.